申请人:Tokyo Tanabe Company, Limited
公开号:US04418197A1
公开(公告)日:1983-11-29
Novel 1,4-dihydropyridine derivatives of the formula [I] are provided: ##STR1## wherein R.sup.1 represents a C.sub.1-4 alkyl group or a C.sub.3-6 alkoxyalkyl group, R.sup.2 represents hydrogen or halogen, R.sup.3 is either nitro when R.sup.2 is hydrogen, or halogen when R.sup.2 is halogen, R.sup.4 represents a pyridyl group, a phenethyl group, an unsubstituted benzyl group, a substituted benzyl group having one or more suitable substituents, an unsubstituted phenyl group, or a substituted phenyl group having one or more suitable substituents, and A represents an unsubstituted hexamethylene group or a substituted hexamethylene group having one or two C.sub.1-3 alkyl groups. The 1,4-dihydropyridine derivatives have vasodilating and hypotensive activity which is kept for a long period, and are useful in the treatment of cardiovascular disease and hypertension.
提供了公式[I]的新颖1,4-二氢吡啶衍生物:其中R.sup.1代表C.sub.1-4烷基或C.sub.3-6烷氧基烷基,R.sup.2代表氢或卤素,R.sup.3在R.sup.2为氢时是硝基,或在R.sup.2为卤素时是卤素,R.sup.4代表吡啶基、苯乙基、未取代苄基、具有一个或多个适当取代基的取代苄基、未取代苯基或具有一个或多个适当取代基的取代苯基,A代表未取代的己亚甲基或具有一个或两个C.sub.1-3烷基的取代己亚甲基。这些1,4-二氢吡啶衍生物具有持续的扩血管和降压活性,并且在心血管疾病和高血压的治疗中很有用。